This review highlights the molecular mechanisms by which hERG K+ channels regulate cell cycle and death in cancer cells, suggesting their potential as targets for anticancer therapy.
hERG-targeted agents require cardiac safety validation before trials; leaves open clinical efficacy in oncology.
The human ether-a-go-go-related gene potassium channel (hERG, Kv11.1, KCNH2) has an essential role in cardiac action potential repolarization. Electrical dysfunction of the voltage-sensitive ion channel is associated with potentially lethal ventricular arrhythmias in humans. hERG K(+) channels are also expressed in a variety of cancer cells where they control cell proliferation and apoptosis. In this review, we discuss molecular mechanisms of hERG-associated cell cycle regulation and cell death. In addition, the significance of hERG K(+) channels as future drug target in anticancer therapy is highlighted.
No takes yet. Share an insight, caveat, or question.
Jehle et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: